Intended for healthcare professionals


Drug company issues warning about flu drug

BMJ 2000; 320 doi: (Published 05 February 2000) Cite this as: BMJ 2000;320:334
  1. Gavin Yamey
  1. BMJ

    GlaxoWellcome issued a warning letter to doctors across Europe last week that its drug for treating influenza, zanamivir (Relenza), could cause bronchospasm and serious respiratory deterioration.

    The company now advises doctors to use special caution in prescribing the drug to patients with underlying asthma or chronic obstructive pulmonary disease. Such patients, it suggests, should …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription